Urania Therapeutics

Founded in 2015 and headquartered in France, Urania Therapeutics develops therapies specifically designed to address genetic diseases associated with nonsense mutations. The company has undergone strategic pivots to enhance its focus on READTHROUGH compounds.Urania Therapeutics specializes in developing innovative treatments for genetic diseases and cancers resulting from nonsense mutations. The company focuses on creating READTHROUGH compounds, which aim to restore the synthesis of full-length proteins by bypassing deleterious mutations via a gene-independent mechanism at the ribosomal level. This approach addresses a significant therapeutic gap in monogenic diseases, which collectively affect around 300 million people globally. Urania's primary customer base includes hospitals and healthcare providers that serve patients suffering from these genetic conditions, particularly those with nonsense mutations that account for 10-15% of cases.Urania Therapeutics generates revenue through partnerships and collaborations with research institutions, pharmaceutical companies, and healthcare providers focused on rare disease treatments. The company’s business model may involve licensing agreements for their READTHROUGH compounds, which would allow partners access to their proprietary drug candidates in exchange for upfront fees and royalties on future sales. Additionally, Urania may engage in grant-funded research initiatives to support their R&D activities while bolstering their financial foundation. The transactions typically revolve around collaborative development agreements, where Urania's innovative drug designs are integrated into broader therapeutic pipelines, facilitating commercialization efforts in exchange for revenue-sharing agreements. The company is focused on launching new products aimed at treating genetic diseases caused by nonsense mutations, targeting a market launch by 2023. Moreover, Urania aims to expand its presence in European and North American markets, aiming to establish strategic partnerships within these regions to enhance its distribution capabilities. These initiatives are designed to position the company favorably in addressing the significant unmet needs of patients suffering from genetic disorders.

1. Series A

   Jul 15, 2021

   Amount

   $0.9M

   Investors

   Locked

2. Series A

   Sep 11, 2020

   Amount

   $1.9M

   Investors

   Locked

3. Series A

   Nov 29, 2019

   Amount

   $0.9M

   Investors

   Locked